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Abstract  
 
Objectives: To compare non-inferiority margins defined in study protocols and records in trial registries with 
margins reported in subsequent publications.  
Study design and setting: Comparison of protocols of non-inferiority trials submitted 2001 to 2005 to ethics 
committees in Switzerland and The Netherlands with corresponding publications and registry records. We 
searched MEDLINE via PubMed, the Cochrane Controlled Trials Register (Cochrane Library issue 01/2012) 
and Google Scholar in September 2013 to identify published reports, and the International Clinical Trials 
Registry Platform (ICTRP) of the World Health Organization (WHO) in March 2013 to identify registry 
records. Two readers recorded the non-inferiority margin and other data using a standardized data abstraction 
form. 
Results: The margin was identical in study protocol and publication in 43 (80%) of 54 pairs of study 
protocols and articles. In the remaining pairs reporting was inconsistent (5 pairs, 9%), or the non-inferiority 
margin was either not reported in the publication (5 pairs, 9%) or not defined in the study protocol (1 pair). 
The confidence interval or the exact P-value required to judge whether the result was compatible with non-
inferior, inferior or superior efficacy was reported in 43 (80%) publications. Complete and consistent 
reporting of both non-inferiority margin and confidence interval (or exact P-value) was present in 39 (72%) 
protocol-publication pairs. Twenty-nine trials (54%) were registered in trial registries, but only one registry 
record included the non-inferiority margin. 
Conclusion: The reporting of non-inferiority margins was incomplete and inconsistent with study protocols in 
a substantial proportion of published trials, and margins were rarely reported in trial registries.  
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1. Introduction 
A non-inferiority trial (NIT) measures a new treatment against a standard treatment to determine if it is not 
substantially worse.  NITs are useful when benefits of standard therapy are known, and when novel treatments 
may be easier to use, less costly, or have fewer side effects [1].  NITs can also test pharmacologically related 
compounds to see if they are similarly effective [2].  A new treatment is considered non-inferior if the trial 
demonstrates that the new treatment is unlikely to be worse than an established treatment by more than a pre-
specified amount, the non-inferiority margin. A non-inferiority margin that is too wide may compromise the 
results, and encourage acceptance and use of less effective therapies [3,4].  The number of published non-
inferiority studies has substantially in recent years [5]. 
The interpretation of results of non-inferiority trials is challenging [4]. It requires an assessment of the 
rationale for the design and the assumptions underlying the choice of the non-inferiority margin [6]. Since 
readers have generally no access to study protocols the complete and accurate reporting of what was planned 
is essential [7].  Guidelines for the design and conduct of NITs have been issued by the International 
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use 
(ICH)[8] and by the Committee for Medicinal Products for Human Use (CHMP) [9].  The Consolidated 
Standards of Reporting Trials (CONSORT) statement has been extended to improve the reporting of such 
trials [7].  The integrity of the NIT cannot be affirmed if authors do not accurately report the pre-specified 
non-inferiority margins and the relevant confidence intervals [10]. Authors must document the margins 
selected during the planning phase, and ensure that these margins are not chosen or modified post hoc, during 
analysis [4]. 
Some investigators modify design elements of a study, driven by their results. The post hoc 
modification of outcomes in randomized trials is a well-documented practice [11,12]. For example, a recent 
study of almost 3000 outcomes of (superiority) trials submitted to an ethics committee in Switzerland showed 
that in 30% of studies there were discrepancies between definitions in the protocols and in publications [13].  
The risk of incorrect reporting is potentially greater for NITs than for superiority trials.  In superiority trials 
the tested hypothesis is always the null hypothesis of no difference, which cannot be altered a posteriori. If the 
confidence interval on the difference includes 0, the new treatment is considered to be no better than the 
Published in final edited form as: J Clin Epidemiol. 2015 May;68(5):510-7. doi: 10.1016/j.jclinepi.2014.09.015 
  4 
reference treatment. In contrast, an NIT tests the hypothesis that the new treatment is less effective than the 
reference treatment by an acceptable amount, captured by the non-inferiority margin. Because the choice of 
the margin is to some extent arbitrary, researchers may be tempted to redefine the margin once the results are 
in, to claim non-inferiority. At present it is unknown whether this happens or not.  
Our goal was to compare protocols of NITs submitted to ethics committees with published articles 
reporting the results of these NITs. We assessed the non-inferiority margins reported in protocols and 
publications, with the intent of determining whether the margins were concordant between protocols and 
publications. We also identified the studies that had been registered in a publicly accessible trial registry and 
examined whether or not the non-inferiority design and margin had been included in the registry record. 
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2. Methods 
2.1 Identification of protocols of non-inferiority trials 
In July 2012 we searched for protocols of non-inferiority trials in databases and archives of three research 
ethics committees: Kantonale Ethikkommission Bern (the Canton of Bern, Switzerland, see www.kek-
bern.ch); Commission d’éthique de la recherche sur l’être humain (the Ethics Commission of University 
Hospitals of Geneva, Switzerland, see www.hug-ge.ch/ethique); and Ethische Commissie Leids Universitair 
Medisch Centrum (the ethics committee of Leiden University Medical Centre in the Netherlands, 
www.lumc.nl). We restricted our search to protocols submitted between January 1, 2001 and December 31, 
2005. The non-inferiority design is relatively new, and few non-inferiority studies were published before 2001 
[14].  We chose a cut-off date at the end of 2005 to allow enough time for the studies to be conducted and 
published.  
A study protocol was eligible for inclusion if it described a non-inferiority or equivalence trial or 
stated that its goal was to determine whether a treatment was no worse than its comparator. When reviewing 
protocols for eligibility, we paid particular attention to the summary description of the study, the hypothesis 
that was tested, the statistical methods, and the determination of sample size. We included all non-inferiority 
trials, without regard to the number of arms, the intervention examined, or the inclusion of a non-inferiority 
margin in the protocol.  
2.2 Identification of matching publications 
In September 2012 we systematically searched for subsequent publications of each included study protocol in 
PubMed (National Library of Medicine), the Cochrane Collaboration’s CENTRAL register of controlled 
clinical trials[15] (Cochrane Library, issue 01/2012), and Google Scholar. The CENTRAL database includes 
trials published in journals not indexed in MEDLINE, EMBASE or other bibliographic databases and in 
languages other than English. We searched for publications that used the study name or acronym (if available), 
combined with the condition studied, the intervention evaluated in the study and the names of the applicants. 
We included full text articles published in a medical journal. If more than one publication resulted from the 
same non-inferiority trial, we assessed the main publication. No language restrictions were applied to any of 
the searches.  
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2.3 Identification of registry records 
In March 2013, we searched for registry records of each included study protocol in publicly accessible trial 
registries. We used the registration number reported in the publication or searched by study title, interventions 
and outcome in the International Clinical Trials Registry Platform (ICTRP) of the World Health Organization 
(WHO). The ICTRP search platform covers over ten trial registries, including ClinicalTrials.gov.  
2.4 Data collection and definitions 
We used a pre-tested, standardized data extraction form for study protocols, trial registry records and 
publications. Data were extracted by one investigator in each center (AP, JB MC, or OMD) and cross-checked 
by a second (MC, ME, OMD, SA, or TP).  Discrepancies were resolved by consensus between the 
investigators. We extracted the following information from the study protocols (and, if available, from trial 
registry records): applicants, number and location of study centers, primary outcome, non-inferiority margin 
for the primary outcome, type of outcome (relative risk, risk difference, difference in continuous variables), 
type of experimental and control intervention (drug, device, surgical technique), planned sample size, subject 
area and source of funding (industry or non-commercial). Industry funding was defined as any financial 
support or provision of study materials by the pharmaceutical industry. If amendments were submitted, we 
considered the information in the latest amendment to be the correct protocol-defined non-inferiority margin. 
From published reports we extracted the year of publication, journal, reported study design, verdict regarding 
the experimental treatment (non-inferior, inferior, superior, inconclusive), and the upper limit of the 
confidence interval used to determine non-inferiority or exact p value.  
2.5 Data analysis 
We examined whether the non-inferiority margin reported in the publication was identical to the margin 
defined in the study protocol. We classified pairs of non-inferiority margins as concordant or discordant; the 
latter group was further divided by the direction of the difference (margin in the publication was larger or 
smaller than the margin in the protocol). For discordant cases, we assessed whether the change in the margin 
between protocol and publication also changed the verdict to non-inferiority. We examined whether the 
confidence interval of the estimate of the treatment effect was reported for the primary outcome. Information 
about both confidence interval and non-inferiority margin are necessary to reproduce the authors’ verdict on 
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non-inferiority. If no confidence interval was reported we looked for a statistical test of non-inferiority. 
Complete and consistent reporting was defined as adequate reporting of both non-inferiority margins and 
confidence interval or exact p-value. We examined whether the sample size, industry funding or year of 
publication were associated with complete and consistent reporting in a logistic regression model. Finally, we 
identified trials that were described as non-inferiority trials in the protocol but described differently (for 
example as a superiority trial) in the publications. Data were analyzed using Stata software (version 12, 
College Station, Texas, USA). 
2.6 Ethical approval 
The ethics committees participating in this study and the authorities responsible for data protection in Bern 
and Geneva, Switzerland and Leiden, The Netherlands approved access to study protocols and their use for 
this research project. In Bern the approval was given under the condition that authors of included studies are 
not identified.  
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3. Results 
3.1 Identification of eligible protocols and publications 
We identified 123 eligible protocols that had been submitted to one of the three participating ethics 
committees (Bern, Geneva and Leiden) between January 1, 2001 and December 31, 2005 (Figure 1). We 
removed duplicates and then searched for publications that matched one of 115 unique study protocols. From 
these, we identified 54 publications, published between 2004 and 2012. The median year of submission to the 
ethics committee was 2003 both for protocols with and protocols without publication. 
3.2 Characteristics of protocols and published reports 
Table 1 summarizes the characteristics of the 54 study protocols and corresponding publications. Forty-one 
(76%) trials were described as NITs and 13 (24%) as equivalence trials. Most trials were from the fields of 
infectious (15 trials) or vascular diseases (6), hematology (5) and diabetes (5). Publications increased in 
number from one in 2004 to thirteen in 2008 and decreased thereafter to three in 2011, and six in 2012. The 54 
included studies were published in 37 different journals. Most studies were multicenter trials (51; 94%) and 
included countries other than Switzerland or The Netherlands (47; 92%). Most studies had planned sample 
sizes of 600 patients or more (33; 61%); most tested drugs (44; 81%) and received funding from the 
pharmaceutical industry (44; 81%).  
Forty trials (74%) concluded that new treatments were non-inferior or equivalent; ten (19%) reported 
that the experimental intervention was superior to the control intervention; three (6%) reported that results 
were inconclusive (i.e. the confidence interval for the difference in treatment effects included the non-
inferiority margin); one trial reported the new treatment was inferior (i.e. the confidence interval for the 
difference in treatment effects was below the non-inferiority margin).  
3.3 Completeness and consistency of reporting 
The authors of 50 publications (93%) explicitly reported the study design as a non-inferiority (or equivalence) 
trial or as a combined superiority and non-inferiority trial. Two publications were reported as superiority 
trials; two publications did not mention the design. Table 2 details the reporting of non-inferiority margins in 
study protocols and matching publications, and the reporting of the relevant confidence intervals in 
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publications. In 43 (80%) of 54 pairs of study protocols and articles, non-inferiority margins were identical in 
study protocols and publications. In the remaining pairs reporting was inconsistent (5 pairs, 9%), or the non-
inferiority margin was either not reported in the publication (5 pairs; 9%) or not defined in the study protocol 
(1 pair). The confidence interval or exact p-value required to judge whether the result was compatible with 
non-inferior, inferior or superior efficacy of the experimental treatment was reported in 43 (80%) publications.  
Complete and consistent reporting of both non-inferiority margins and confidence interval (or exact p-value) 
was present in 39 (72%) protocol-publication pairs. Table 3 shows the characteristics of the studies with 
inconsistent or incomplete reporting. In a logistic regression model complete and consistent reporting was not 
associated with sample size (p=0.54), industry funding (p=0.82) or year of publication (p=0.50). 
3.4 Reassessment of inconsistent and incomplete results  
We reassessed the conclusion of non-inferiority for the 11 protocol-publication pairs that reported the non-
inferiority margin inconsistently (5 pairs) or incompletely (6 pairs). The margin was wider in the publication 
than in the protocol for four trials. The protocol had a larger margin than the publication for one trial. The five 
inconsistent trials concluded that results demonstrated non-inferiority (4 trials) or superiority (1 trial). We 
found that these conclusions remained unchanged, even when we reassessed them in the light of the margin 
defined in the protocol.  
The non-inferiority margin was not reported in the publication for five protocol-publication pairs. 
Among these five, the confidence interval appeared in one publication. For that study, the upper limit of the 
confidence interval reported in the publication was within the non-inferiority margin specified in the protocol. 
The missing confidence intervals in the publications of the remaining four pairs prevented us from assessing 
results in the light of the non-inferiority margin reported in the protocol. The single study that did not define 
the non-inferiority margin in the protocol did report it in the publication, but gave no confidence intervals.  
3.5 Registry records 
Out of 54 study protocols with matching publications, we identified 29 trials (54%) in publicly accessible 
registries. Twenty-eight were from Clinical.Trials.gov. The non-inferiority design was reported in five of 
these registry records (17%). Only one record (3%) reported the non-inferiority margin, which was consistent 
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with the one reported in the published report. Most trials (28, 97%) were registered before publication, 23 
trials (82%) within one year after the study had been approved by the ethics committee, and 5 trials (18%) 
within two to five years. One trial was entered in the registry after publication. 
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4. Discussion 
We compared the non-inferiority margins reported in study protocols approved by ethics committees in 
Switzerland and The Netherlands with the margins reported in subsequent publications. We found that non-
inferiority margins had changed from protocol to published report in 5 (9%) out of 54 trials, but these changes 
did not affect the conclusions on non-inferiority. In a further 10 trials (19%) reporting was incomplete and in 
these cases it was generally not possible to reproduce the authors’ conclusions regarding non-inferiority of the 
experimental intervention. Although our study did not show that researchers willfully manipulate non-
inferiority margins, the incomplete reporting of results also meant that this could not be ruled out in a 
substantial proportion of trials.  
 Only about half of trials had been registered in a trial registry. The International Committee of 
Medical Journal Editors (ICMJE) requires public, prospective registration of clinical trials that began on or 
after July 1, 2005 [16]. For the present project, we included trials initiated between 2001 and 2005. The low 
registration rate for the trials we included might result from the failure of investigators to comply with the 
ICMJE request to retrospectively register all trials initiated before July 1, 2005. Our study confirms the results 
of a previous study from our group that compared publication of non-inferiority studies to information 
publicly accessible in trial registries. The study showed only 35 of 87 registry records described the design of 
the study as a NIT and only one record reported the non-inferiority margin [10]. For the present project, we 
included trials initiated between 2001 and 2005. The low registration rate for the trials we included might 
result from the failure of investigators to comply with the ICMJE request to retrospectively register all trials 
initiated before July 1, 2005. 
We identified publications from 54 of 116 study protocols (46%). Although we conducted an 
extensive literature search we may have missed some publications because of delays between acceptance and 
publication of the manuscript, or because the study protocol did not provide sufficient information (e.g., name 
of all investigators involved in the study, brand name of intervention) to identify the publications that resulted 
from the study. We did not contact investigators to inquire about publications that we may have missed. Based 
on the experience gained in a previous study of protocols of drug trials and subsequent publications, about 
seven additional publications might have been identified in this way [17]. In the previous study, 233 out of 
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451 study protocols resulted in at least one publication, for a publication rate of 52% [17]. Studies of research 
proposals submitted to research ethics committees in France [18] and Spain [19] reported lower rates of 
publication (38% and 31%, respectively) whereas an older study from the United States of America reported 
higher rates (above 60%) [20].   
Our aim was to examine protocol-publication pairs for consistent and transparent reporting. We did 
not assess whether the study design was appropriate for answering the research question. Nor did we check if 
the non-inferiority margin was used to correctly calculate the sample size [21], or whether it was considered 
in the statistical analysis plan of the study protocol. The methodological and reporting quality of reports of 
non-inferiority publications has been studied previously. One review of non-inferiority trials found that 
approximately only one fifth of the non-inferiority and equivalent studies provided an adequate rationale for 
the non-inferiority margin [22]. A study of the reporting quality of non-inferiority trials published 2003 to 
2004 [23] found that less than 20% of the studies reported a clinical consideration and a justification of the 
margin. In the latter study the non-inferiority margin was not reported in only few articles (in six of 162 
articles [3.7%]). Similarly, only five (2.2%) out of 232 non-inferiority trials identified in a PubMed search in 
2009 did not report the margin, but less than half of the trials reported the method to determine the margin 
[24]. In our study the margin was missing somewhat more frequently in the published articles (in five of 54 
articles [9.3%], despite the fact that many of these studies were published more recently, after guidance on the 
transparent reporting of such trials had become available [25]. The extension to the Consolidated Standards of 
Reporting Trials (CONSORT) for non-inferiority and equivalence trials was first published in 2006 [25] and 
updated in 2012 [7]. The CONSORT reporting guidelines stress the importance of specifying the margins of 
non-inferiority or equivalence and the rationale for their choice [7,25].  
Another limitation of our study is the relatively small sample size of our study: it is possible that a 
larger study might identify predictors associated with consistent and complete reporting of non-inferiority 
margins and confidence interval or p-values. For example, in a previous study of 227 protocol-publication 
pairs of drug trials we found that discrepant reporting of outcomes was more likely for smaller trials than for 
larger trials [13]. An important strength of the present study is that we had unrestricted access to the databases 
and archive of the three Ethics Committees. We could thus include an unselected sample of non-inferiority 
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studies submitted between 2001 and 2005 to one of three ethics committees in two European countries. 
However, the published trials included in this study may not be representative of all non-inferiority trials 
published in the literature. Indeed, compared to our study a sample of 232 non-inferiority trials identified in a 
PubMed search in 2009 included a larger proportion of smaller trials, with intermediate endpoints, and more 
trials sponsored by independent investigators [24]. Our study was dominated by larger, international 
multicenter trials funded by the pharmaceutical industry.  
Finally, although this study is the first to empirically compare the reporting of the non-inferiority 
margin between study protocols and the subsequent publications but it reflects the earlier phase of the rise of 
non-inferiority and equivalence trials and may no longer be applicable to the studies submitted to ethics 
committees and institutional review boards today. The study should be repeated in the future to monitor the 
reporting of non-inferiority margins in study protocols and corresponding publications.  
In conclusion, our findings emphasize that adhering to guidelines for protocol preparation and 
reporting recommendations is essential to the design and reporting of non-inferiority trials. At planning stage, 
recommendations about statistical considerations and the choice of non-inferiority margin should guide the 
development of protocols [26] and ensure their completeness. The non-inferiority margin must be specified in 
a study’s planning stage and documentation of the margin must be transparent and complete so that the results 
of the study can be interpreted. As argued previously [10], trial registries should modify their databases so that 
the non-inferiority design and in particular the non-inferiority margin can be recorded in the registry. At 
publishing stage adherence to the extension of the CONSORT reporting guidelines to non-inferiority trials [7] 
will improve reports of non-inferiority trials. Our results support the addition of an item explicitly asking 
authors to report ‘‘any changes to non-inferiority margin after the trial commenced, with reasons’’ to a future 
update of the reporting guidelines. Finally, at reviewing stage, reviewers and editors should examine research 
protocols and plans for statistical analysis and ask authors to make such documents publicly available, as 
recommended by the ICMJE [27].  
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Figure 1: Flow diagram for selection of included study protocols and subsequent publications 
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Table 1. Characteristics of 54 study protocols and matching publications of non-inferiority trials submitted to 
three ethics committees in Switzerland and The Netherlands 2001 to 2005. 
 
Study characteristics No. (%) 
Field of medicine  
Infectious diseases 15 (28) 
Vascular diseases 6 (11) 
Diabetology 5 (9) 
Hematology 5 (9) 
Rheumatology 4 (7) 
Other 19 (35) 
Publication year  
2004 to 2006 15 (28) 
2007 to 2009 24 (44) 
2010 to 2012 15 (28) 
Number of centers  
Multicenter 51 (94) 
Single center 3 (6) 
Source of funding  
Industry 44 (81) 
   Other 10 (19) 
Type of outcome specified in protocol  
Binary outcome 32 (59) 
Continuous outcome 15 (28) 
Time-to event 7 (13) 
Planned sample size in protocol  
<400 11 (20) 
400 to <600 10 (19) 
600 to <1000 20 (37) 
>1000 13 (24) 
Type of intervention  
   Drug 44 (81) 
   Other 10 (19) 
Journal of publication  
Lancet 9 (17) 
New England Journal of Medicine 3 (6) 
American Journal of Transplantation 2 (4) 
Antimicrobial Agents and Chemotherapy 2 (4) 
Clinical Microbiology and Infection 2 (4) 
Current Medical Research Opinion 2 (4) 
Movement Disorders 2 (4) 
Pediatric Blood Cancer 2 (4) 
Other 24 (44) 
Verdict reported in the publication  
Non-inferior or equivalent 40 (74) 
Superior 10 (19) 
Inferiority not rejected 3 (6) 
Inferior 1 (2) 
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Table 2. Reporting of non-inferiority margins in 54 study protocols and matching publications and reporting 
of the relevant confidence intervals in publications. 
 
 No. (%) 
Non-inferiority margin identical in protocol and publication 43 (79) 
Non-inferiority margin differs between protocol and publication 5 (9) 
Margin wider in publication than in protocol 4 (7) 
Margin wider in protocol than in publication 1 (2) 
Incomplete reporting of non-inferiority margin  6 (11)  
Margin reported in study protocol but not in publication 5 (9) 
Margin reported in publication but not in protocol 1 (2) 
Confidence interval or p-value for non-inferiority test  
Reported in publication 43 (80) 
Not reported in publication 11 (20) 
Complete and consistent reporting* 39 (72) 
 
* Non-inferiority margins identical in protocol and publication and relevant confidence interval reported or p-value for 
the non-inferiority test reported in publication.   
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Table 3. Characteristics of 15 non-inferiority studies with inconsistent or incomplete reporting.  
 
 
Field Year Industry involved 
Type of 
margin 
Non-inferiority  
margin 
Upper limit of 
confidence 
interval 
Authors’ 
conclusion 
 
 
   Protocol Publication   
 
Inconsistent reporting 
 
Infectious 
Diseases 2004 Yes 
Risk 
difference -0.12 -0.10 -0.012 Non-inferior 
Diabetology 2005 Yes Risk difference 0.13 0.15 0.007 Non-inferior 
Neurology 2007 Yes Mean difference 0.33 3 -4.7 Superior 
Diabetology 2010 Yes Mean difference 0.3 0.4 0.2 Non-inferior 
Intensive care 
medicine 2012 Yes 
Mean 
difference -0.1 -0.15 -0.03 Non-inferior 
 
Incomplete reporting 
 
Infectious 
diseases 2008 No 
Risk 
difference 
Not 
reported 0.04 Not reported Non-inferior 
Cardiology 
 
2005 Yes Risk difference 0.08 
Not 
reported Not reported Superior 
Endocrinology 
 
2008 Yes Mean difference -0.01 
Not 
reported Not reported Non-inferior 
Diabetology 
 
2009 Yes Mean difference 0.4 
Not 
reported 0.1 Non-inferior 
Anesthesiology 
 
2009 Yes Risk difference -0.05 
Not 
reported Not reported Non-inferior 
Vascular Medicine 2010 No Risk difference 0.015 
Not 
reported Not reported Non-inferior 
Ophtalmology 
 
2007 Yes Mean difference 1 1 Not reported Non-inferior 
Rheumatology 
 
2008 Yes Mean difference -0.5 -0.5 Not reported Non-inferior 
Neurology 
 
2007 Yes Mean difference -0.15 -0.15 Not reported Inconclusive 
Infectious 
diseases 2007 Yes 
Risk 
difference -0.1 -0.1 Not reported Non-inferior 
 
 
 
